Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Identifieur interne : 000627 ( PubMed/Corpus ); précédent : 000626; suivant : 000628Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Auteurs : Fabienne Ory-Magne ; Jean-Christophe Corvol ; Jean-Philippe Azulay ; Anne-Marie Bonnet ; Christine Brefel-Courbon ; Philippe Damier ; Estelle Dellapina ; Alain Destée ; Franck Durif ; Monique Galitzky ; Thibaud Lebouvier ; Wassilios Meissner ; Claire Thalamas ; François Tison ; Alexandrine Salis ; Agnès Sommet ; François Viallet ; Marie Vidailhet ; Olivier RascolSource :
- Neurology [ 1526-632X ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome.
Abstract
The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID).
DOI: 10.1212/WNL.0000000000000050
PubMed: 24371304
Links to Exploration step
pubmed:24371304Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.</title><author><name sortKey="Ory Magne, Fabienne" sort="Ory Magne, Fabienne" uniqKey="Ory Magne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><nlm:affiliation>From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France.</nlm:affiliation></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name></author><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name></author><author><name sortKey="Lebouvier, Thibaud" sort="Lebouvier, Thibaud" uniqKey="Lebouvier T" first="Thibaud" last="Lebouvier">Thibaud Lebouvier</name></author><author><name sortKey="Meissner, Wassilios" sort="Meissner, Wassilios" uniqKey="Meissner W" first="Wassilios" last="Meissner">Wassilios Meissner</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name></author><author><name sortKey="Salis, Alexandrine" sort="Salis, Alexandrine" uniqKey="Salis A" first="Alexandrine" last="Salis">Alexandrine Salis</name></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name></author><author><name sortKey="Viallet, Francois" sort="Viallet, Francois" uniqKey="Viallet F" first="François" last="Viallet">François Viallet</name></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24371304</idno><idno type="pmid">24371304</idno><idno type="doi">10.1212/WNL.0000000000000050</idno><idno type="wicri:Area/PubMed/Corpus">000627</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000627</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.</title><author><name sortKey="Ory Magne, Fabienne" sort="Ory Magne, Fabienne" uniqKey="Ory Magne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><nlm:affiliation>From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France.</nlm:affiliation></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Bonnet, Anne Marie" sort="Bonnet, Anne Marie" uniqKey="Bonnet A" first="Anne-Marie" last="Bonnet">Anne-Marie Bonnet</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name></author><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author><author><name sortKey="Galitzky, Monique" sort="Galitzky, Monique" uniqKey="Galitzky M" first="Monique" last="Galitzky">Monique Galitzky</name></author><author><name sortKey="Lebouvier, Thibaud" sort="Lebouvier, Thibaud" uniqKey="Lebouvier T" first="Thibaud" last="Lebouvier">Thibaud Lebouvier</name></author><author><name sortKey="Meissner, Wassilios" sort="Meissner, Wassilios" uniqKey="Meissner W" first="Wassilios" last="Meissner">Wassilios Meissner</name></author><author><name sortKey="Thalamas, Claire" sort="Thalamas, Claire" uniqKey="Thalamas C" first="Claire" last="Thalamas">Claire Thalamas</name></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name></author><author><name sortKey="Salis, Alexandrine" sort="Salis, Alexandrine" uniqKey="Salis A" first="Alexandrine" last="Salis">Alexandrine Salis</name></author><author><name sortKey="Sommet, Agnes" sort="Sommet, Agnes" uniqKey="Sommet A" first="Agnès" last="Sommet">Agnès Sommet</name></author><author><name sortKey="Viallet, Francois" sort="Viallet, Francois" uniqKey="Viallet F" first="François" last="Viallet">François Viallet</name></author><author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Neurology</title><idno type="eISSN">1526-632X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amantadine (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24371304</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>28</Day></DateCreated><DateCompleted><Year>2014</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.</ArticleTitle><Pagination><MedlinePgn>300-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000050</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a 3-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group, wash-out study conducted in 57 amantadine-treated (≥200 mg/d for ≥6 months) dyskinetic patients with PD. The primary outcome measure was the change from baseline in a Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia subscore (items 32 [duration] + 33 [severity]). Secondary outcomes included other LID measurements ("responders" analysis, premature dropout for LID, Abnormal Involuntary Movement Scale). Exploratory outcomes included time with troublesome dyskinesia as measured by diaries, UPDRS Motor Examination (part III) for motor symptoms of PD, and fatigue and apathy scores for nonmotor symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">UPDRS items 32 + 33 deteriorated more in patients switched to placebo ("discontinuing" group) (+1.7 ± 2.0 units; 95% confidence interval 0.9, 2.4) as compared with those maintained on amantadine ("continuing" group) (+0.2 ± 1.5 units; 95% confidence interval -0.4, 0.8; p = 0.003). Secondary outcomes confirmed this difference because there were significantly more responders, more dropouts for LID, greater increase in "ON" time with troublesome dyskinesia, and greater worsening of Abnormal Involuntary Movement Scale score in the discontinuing group. There were no between-group differences in the UPDRS Motor Examination, whereas apathy (as measured by caregivers) and fatigue scores tended to worsen more in patients randomized to placebo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Wash-out of amantadine in dyskinetic patients with PD significantly worsened LID. No significant effect was observed on motor parkinsonian symptoms, while exploratory outcomes suggested that amantadine might improve apathy and fatigue in such patients.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This article provides Class II evidence that in patients with PD, withdrawing amantadine significantly aggravates LID in a median time of 7 days.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ory-Magne</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From INSERM, Clinical Investigation Center 9302 (F.O.-M., C.B.-C., E.D., M.G., C.T., A.S., O.R.), and Department of Neurology (F.O.-M., C.B.-C., O.R.), University Hospital of Toulouse; INSERM, Clinical Investigation Center 9503 (J.-C.C., A.-M.B., M.V.), and AP-HP, Department of Neurology (J.-C.C., A.-M.B., M.V.), Pitié-Salpêtrière Hospital, Paris; CRICM UPMC/INSERM UMR_S975 CNRS UMR7225 (J.-C.C., M.V.), Institut de la Moelle et du Cerveau, Université Pierre Marie Curie Paris-6, Salpêtrière, Paris; AP-HM (J.-P.A.), Department of Neurology, Timone Hospital, Marseille; Department of Clinical Pharmacology (C.B.-C., C.T., A.S., O.R.), University of Medicine, Toulouse; INSERM (C.B.-C., O.R.), and Université de Toulouse, UPS (C.B.-C., O.R.), Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse; Department of Neurology (P.D., T.L.), University Hospital of Nantes; Department of Neurology (A.D.), University Hospital of Lille; Department of Neurology (F.D.), University Hospital of Clermont-Ferrand; Department of Neurology (W.M., F.T.), University Hospital of Bordeaux; and Department of Neurology (F.V.), Pays-d'Aix Hospital, Aix-en-Provence, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Azulay</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dellapina</LastName><ForeName>Estelle</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Galitzky</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lebouvier</LastName><ForeName>Thibaud</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Meissner</LastName><ForeName>Wassilios</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Thalamas</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Salis</LastName><ForeName>Alexandrine</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sommet</LastName><ForeName>Agnès</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Viallet</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><CollectiveName>NS-Park CIC Network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Sep 9;83(11):1035-6</RefSource><PMID Version="1">25200717</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Sep 9;83(11):1036</RefSource><PMID Version="1">25340202</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24371304</ArticleId><ArticleId IdType="pii">WNL.0000000000000050</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000050</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000627 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000627 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24371304
|texte= Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24371304" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |